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secretion in metastatic neuroendocrine (NE) cancers. (2) To evaluate the
expression pattern of SV2 receptors in NE cancer patient-derived tissues for
prediction of patient response for recombinant HCR (rHCR) treatment. (3) To
assess the in vivo efficacy and toxicity of rHCR in a NE cancer liver metastasis
mouse models and in the NE patient-derived 3D MicroTumor system. (4) To
collect preclinical data to design and conduct a clinical trial with NE cancer
patients, a major goal toward translating our discoveries into much needed
therapies. METHODS/STUDY POPULATION: Recombinant botulinum heavy
chain (rHCR) was produced using an IPTG-inducible expression vector in E. coli
BL21. The rHCR was His-Tag purified and stored in PBS buffer before usage.
Cytotoxicity: H727, TT, and MZ cells were plated at a density of 5000 cells/well
in 96-well plates and incubated under standard conditions overnight. The next
day, cells were treated with 10, 100, or 500 nmol/L of rHCR and incubated for
72 hours. Following incubation, cell viability was assessed by ATP quantification
using the CellTiter-Glo (Promega) assay. Fresh NE tumors were dissociated and
injected into polydimethylsiloxane bioreactors in amatrigel and collagen suspension
for 3D culture experiments. The viability of 3D cultures incubated with various
doses of rHCR was assessed by measuring the uptake of the near-infrared dye
IR-783 using an IVIS imaging system. Western blot: H727, TT, and MZ cells were
seeded in 6-well plates at a density of 3×105 cells/well for 24 hours followed by
treatment with 100nmol/L for 72 hours. Total cellular proteins were isolated and
analyzed to assess the level of SV2A expression and the effect of rHCR on the
expression levels of NET marker proteins. Immunohistochemistry: Deparaffinized
tissue culture slides were incubated with SV2A primary antibody in 1% BSA and
incubated overnight at 4°C. Slides were rinsed twice with TBS containing 0.025%
Triton, followed by 0.3% H2O2 for 15 minutes. Slides were then incubated with
HRP-conjugated secondary antibody for 1 hour at room temperature. Detection of
protein-protein interaction: Precleared cell lysate was incubated with glutathione-
agarose beads in the presence of 10μg of GST-tagged rHCR for 2 h at 4°C with
end-over end mixing. Samples were then centrifuged at 10,000 g for 2 minutes and
the supernatant was analyzed by SDS-PAGE. Preclinical models: To allow rHCR
testing on NET patient derived cells in a very novel 3D surrogates, sterile collected
fresh NET tissues will be obtained from the UAB Tissue Procurement, dissociated
into a single cell suspension and injected into a polydimethylsiloxane bioreactors
containing extracellular matrix composed of bovine collagen and matrigel. Such 3D
cell culture will be maintained in bioreactors with constant supply of media through
themicrochannels and treated with rHCR at concentrations ranging from 10nM to
1mM. Following histologic confirmation of growth and morphology of NET
patient-derived 3D surrogates we will test the anticancer activity of rHCR in this
system using the standard cytotoxicity assays as well as we will validate the NET
hormone expression using immunohistochemistry assay. To create an animal
model of NE cancer progression, we will perform intrasplenic injection of NET cell
lines. In approximately 4 weeks, the animals should develop NE liver metastases
based upon our previous experience. rHCR-iFPs accumulation in the tumor mass:
rHCR-iFPs will be injected to the tumor bearing mice after 4 weeks of cells
implantation in 1 week interval for total of 4 treatments at the concentrations of
0.125, 1.25, and 12.5mg/kg. RESULTS/ANTICIPATED RESULTS: Based on the
preliminary data, we expect to detect rHCR-iFPs in NE cancer xenografts and in
patient derived 3D explants. Our preliminary data revealed that treating NETcells
with rHCR significantly reduced NE peptide expression in 3 days. Thus, we expect
to see the decrease of NE tumormarkers even if the fluorescent detection method
is not sensitive enough to monitor the signal. The reduction of the NET markers
can be used as an indicator of the rHCR-iFPs uptake by the tumor mass. If HCR
exhibit high binding affinity to SV2 receptors in NET models but moderate
anticancer efficacy, we plan to use rHCR peptide to conjugate with the nanocarrier
for targeted drug delivery. In this case rHCR peptide can be used as a ligand that
specifically binds to NE cancer cells and delivers anticancer drug. In 3DNET patient
derived explants we expect significant reduction of NET markers and hormones
(serotonin and calcitonin) in NE cancer cells upon long-term rHCR-iFPs treatment.
In addition, wewill performmultiplex protein quantification assay using Luminex to
assess the various hormones, cytokines, and growth factors to be repurposed into a
diagnostic and detection reagent, or a drug delivery ligand for targeted therapies.
DISCUSSION/SIGNIFICANCEOF IMPACT: NE cancers are highly metastatic: NE
cancers such as carcinoid, islet cell tumors, andmedullary thyroid cancer frequently
metastasize to the liver. They are the second most prevalent GI malignancy. Ninety
percent of patients with pancreatic carcinoid tumors and 50% of patients with islet
cell tumors develop isolated hepatic metastases. Patients with untreated, isolated
NE liver metastases have <30% 5-year survival. Thus, there is a critical need for
new therapies for NE cancers. Surgery is the only curative therapy available for
patients with NE cancers but most cannot be cured: surgical removal is the most
effective treatment for NE cancers; however, a very high percentage of patients
present with metastatic disease. While surgical resection can be potentially
curative, many patients are not candidates for operative intervention due to
widespread metastases or the degree of hepatic involvement by the NE cancers.
Moreover, other forms of therapy including chemoembolization, radioemboliza-
tion, cryoablation, and chemotherapy have had limited efficacy. We hope that our
in vitro data on rHCR toxicity and specificity to NET, validated in the pre-clinical
models will allow the first in-human application of this technology in clinical studies.
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OBJECTIVES/SPECIFIC AIMS: Incomplete spinal cord injury typically results in
life-long disability, often in the form of profound loss of locomotion capability.
Individuals who have experienced incomplete spinal cord injury exhibit persistent
eccentric motor deficits, which are particularly prevalent in the weight acceptance
phase of gait and emphasized in sagittal plane knee motion and frontal plane hip
motion. METHODS/STUDY POPULATION: Motion analysis can capture the
kinematic and joint-level deficits of these individuals, but it is impossible to directly
calculate the contributions of individual muscles to weight acceptance due to the
complexity of the musculoskeletal system. Instead, those muscle contributions
must be simulated in order to approximate muscle power during locomotion.
RESULTS/ANTICIPATED RESULTS: The traditional method for driving these
simulations with electromyography readings is unavailable for individuals who have
neuromuscular deficits (e.g., spasticity or paralysis), due to the need to generate
reliable maximum voluntary isometric contractions for baseline purposes. Instead,
this research develops a novel method for using resting electromyography data to
drive musculoskeletal simulations using a muscle activation threshold paradigm.
DISCUSSION/SIGNIFICANCEOF IMPACT: The simulation results of this method
more closely resemble experimental results, but further simulation refinement is
needed to fully capture the true muscle activity.
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OBJECTIVES/SPECIFIC AIMS: Prostate cancer (PCa) is the most common
noncutaneous malignancy in men in the United States. A significant fraction of
advanced PCa treated with androgen deprivation therapy experience relentless
progression to lethal metastatic castration-resistant prostate cancer (mCRPC). The
PCa tumor microenvironment is comprised of a complex mixture of epithelial and
stroma cell types engaged in multifaceted heterotypic interactions functioning to
maintain tumor growth and immune evasion. We recently uncovered the
important role played by myeloid-derived suppressor cells (MDSCs) to mediate
tumor immune evasion in aggressive PCa (Wang, Lu et al., Cancer Discovery,
2016). Immune checkpoint blockade (ICB) has elicited durable therapeutic
responses across a number of cancer types. However, the impact of ICB on
mCRPC has been disappointing, which may signal the need to combine
mechanistically-distinct ICB agents and/or override immunosuppression in the
tumor microenvironment. Our objective is to determine if robust immunotherapy
responses in mCRPC may be elicited by the combined actions of ICB agents
together with targeted agents that neutralize MDSCs yet preserve T cell function.
METHODS/STUDY POPULATION: We created a novel embryonic stem cell-
based chimeric mouse model of mCRPC engineered with signature mutations to
study the response to single and combination immunotherapy. The efficacy studies
were followed with detailed mechanistic investigation and clinical validation.
RESULTS/ANTICIPATED RESULTS: Consonant with early stage clinical trials
experience, anti-CTLA4 or anti-PD1 monotherapy failed to impact disease
progression. Similarly, modest anti-tumor activity was observed with combination
ICB as well as monotherapy with targeted agents including Cabozantinib (tyrosine
kinase inhibitor), Dactolisib (PI3K/mTOR inhibitor), and Dasatinib (tyrosine kinase
inhibitor). In contrast, mCRPC primary and metastatic disease showed robust
responses to dual ICB treatment together with either Cabozantinib or Dactolisib,
but not with Dasatinib which impaired T cell infiltration in the tumor. Detailed
intratumoral immune profiling with mass cytometry (CyTOF) showed that
combined ICB and Cabozantinib or Dactolisib was associated with significant
depletion of MDSCs. Cabozantinib andDactolisib blocked the PI3K signaling activity
in MDSCs and reduced their immunosupppresive activity. Mechanistically, the
combination efficacy was due to the upregulation of IL-1RA and suppression of
MDSC-promoting cytokines secreted by mCRPC cells. DISCUSSION/SIGNIFI-
CANCE OF IMPACT: We demonstrated that an antibody cocktail targeting
CTLA4 and PD1 was insufficient to generate effective anti-tumor response, but
combination of ICB with targeted therapy that inactivates PI3K signaling displayed
superior synergistic efficacy through impairing MDSCs in the tumor microenviron-
ment. These observations illuminate a clinical path hypothesis for combining ICB
with MDSC-targeted therapies in the treatment of mCRPC. Importantly,
conclusions from the study on PCa may have implications in combination
immunotherapy for aggressive breast cancer which is also largely resistant to
immune checkpoint blockade and replete with immunosuppressive myeloid cells.
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